Studies have shown that loss of BRCA2 leads to cells being 100 to 1000 times more sensitive to PARPi, this led to their exploitation in the clinic in the context of BRCA1/2-mutated cancer (2, 3). This evidence concerns the gene BRCA2 and cancer.